Method of Attenuation and Repair of Brain Lesions in Multiple Sclerosis Patients



ACZ is a reversible carbonic anhydrase enzyme inhibitor. This now generic medication has a good safety and tolerability profile, and is known to transiently enhance cerebral perfusion. Enhancing perfusion might improve tissue integrity within areas previously injured.


Technology Overview

- Patients tolerated doses of ACZ up to 4000 mg daily with tolerable side effects.

- Cerebral blow flow (CBF) of healthy controls returned to near baseline within 60 min.

- Increased CBF in MS patients remained present for up to 180 min.

- Pair-wise analysis showed significant increase in CBF at 2000 mg vs 0 mg ACZ in the cortex and deep gray matter

- Cerebral blood flow was increased in brain tissue in MS patients and these findings support further investigation of potential lesion evolution and tissue preservation/repair with cerebral hypoperfusion



Intellectual Property Status

- Patent issued - US10363245B2

- Available for licensing


Stage of Development

- Phase 1 clinical trial complete

- IND obtained for Phase 2 clinical trial


Associated Publications

- Multiple Sclerosis Journal 2014, Vol 20(3) 365-373;

- J of Neuroimmunology 326 (2019) 45-48;




Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Yaya Lai
Technology License Associate
University of Texas Health Science Center At Houston
Jerry Wolinsky
John A Lincoln
Ponnada Narayana
© 2024. All Rights Reserved. Powered by Inteum